Exagen Inc - XGN Enterprise Value-to-Revenue Multiple

Public company logo of Exagen Diagnostics (XGN)

Patent protection for autoimmune disease tests creates a moderate barrier for competitors for Exagen Inc. (XGN). The business relies on its own medical complex, outsourcing couriers and cloud services to external partners. The efficiency of delivering biomaterials to the hub guarantees diagnostic accuracy. The company's valuation via EV/Sales reflects demand dynamics, with the metric holding at 1350.21.

XGN: Exagen Company Value to Revenue 11/23/2025 - 11/20/2026

XGN (Exagen Inc): analytical breakdowns and indicator data

- stock value and consensus price forecast:
- issuer market value details:
Fundamental company valuation:Exagen Inc.
Original product of Exagen

To minimize fundamental risks, investors select assets with a stable ratio of market capitalization to operating revenues. This indicator compares business value to revenue, excluding the impact of debt load to assess pure technological potential. For Exagen Inc. (XGN), this is critical, as pressure from insurance companies limits the final margins of diagnostic tests. By analyzing the company's price-to-sales ratio, one can determine if the asset is overbought. High values for this metric signal inflated market expectations regarding future growth rates.

Direct competitors

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Total Company Value-to-Revenue Ratio MDxHealth Inc.|Enterprise Value-to-Revenue Ratio Lucid Diagnostics, Inc. LUCD|Prenetics Global Ltd (PRE) - Enterprise Value-to-Revenue Multiple|Insight Molecular Diagnostics Inc - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple trinitybiotech.com|PRPH (ProPhase) - Company Value to Revenue|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue